Business Wire

SAB Biotherapeutics' Immunotherapy Proposal among Top Platform Technology Solutions in WHO Report

Del

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company, announced today that its DiversitAb human antibody production platform, leveraging transchromosomic cattle (Tc Bovine™), was identified as of one of the six most meritorious proposals emerging from the World Health Organization (WHO) public consultation on platform technologies for priority infectious diseases with epidemic potential.

This consultation was part of the WHO Research & Development Blueprint, a global strategy and preparedness plan that allows the rapid activation of R&D activities that can be used to save lives and avert large-scale crisis during epidemics. SAB Biotherapeutics’ technology was the only immunotherapy platform among the six finalists (of 35 proposals), which also included three vaccine platforms, a diagnostic technology and a technology covering all product streams.

In October 2015, SAB submitted their proposal, “Targeted Human Immunoglobulin to WHO Priority Pathogens Using Transchromosomic (Tc) Bovine,” which outlined a project over a two-year period to increase their response capability, leveraging a dedicated herd of human antibody producing cattle, to be readily available should an outbreak occur. When needed, the Tc Bovine could be utilized to quickly develop, test, manufacture product and submit to regulators in order to halt the outbreak and help save lives. Targeted human polyclonal immunoglobulins produced in the platform would allow for new solutions and provide an approach that is quickly scalable to be an effective global response.

The WHO sought to identify the most promising R&D platform technologies to combat their priority pathogens including Ebola and MERS, as well as other diseases with epidemic potential such as Zika and Dengue, through a multi-step evaluation process.

“Two key benefits of our unique technology platform are its ability to respond rapidly and produce potent fully-human antibodies to a wide variety of disease targets, including viruses, bacteria, and toxins, in significant quantities,” said Eddie Sullivan, Ph.D., SAB Biotherapeutics president and CEO. “In addition, we have sought to focus our efforts on pathogens including those of priority to the WHO, and have completed several successful studies targeting those potential epidemic threats.”

Proposals were evaluated by an ad hoc Advisory Group (AG) comprising world-renowned experts from medical, scientific and regulatory backgrounds–on their ability to develop and manufacture solutions for clinical trials, in months rather than years, against a variety of infectious disease threats. Other criteria included a favorable benefit-risk profile, scalability, ability to produce sufficient quantities, deliver to low- and middle-income countries (LMICs) and affordability.

The nearly yearlong evaluation included two technical workshops held in Geneva, Switzerland in April and July 2016, where the second showcased the six most “meritorious” proposals for presentation to interested WHO Member States and relevant funders that are also named in the report.

“On behalf of the Biotechnology Innovation Organization (BIO), we congratulate SAB Biotherapeutics for this significant designation by the World Health Organization (WHO),” said Jim Greenwood, BIO President and CEO. “Continued investment in research & development is critical to prevent and combat epidemics. SAB’s immunotherapy platform is just one example of how cutting-edge technologies can lead to life-saving solutions.”

SAB's proposal was presented with LFB (France), Novavax, Inc. (U.S.), United States Naval Medical Research Center, (U.S.); CSIRO Health and Biosecurity Australian Animal Health Laboratory, (Australia) in collaboration to provide vaccine technology, pre-clinical testing protocols and facilities as well as clinical expertise.

“The best way to respond to an outbreak is to prepare before it happens,” added Sullivan. “With this global recognition, we are now seeking funding so these plans can be activated and the technologies are ready–during an epidemic threat–when we need them most.”

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (SAB), headquartered in Sioux Falls, S.D. is a clinical stage, biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.

About World Health Organization

The World Health Organization (WHO) is a specialized global agency whose primary role is to direct and coordinate international health within the United Nations system. It was established on 7 April 1948 and is headquartered in Geneva, Switzerland.

Contact information

SAB Biotherapeutics, Inc.
Melissa Ullerich, 605-695-8350
media@sabbiotherapeutics.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

GSMA: Multiple Mobile Operators Launch Live Commercial Low Power Wide Area Networks in Licensed Spectrum Worldwide21.2.2018 09:00Pressemelding

The GSMA today announced that momentum behind Mobile IoT, or licensed Low Power Wide Area (LPWA), networks continues to grow on a global basis. To date, 23 mobile operators have commercially launched 41 Mobile IoT networks worldwide across both NB-IoT1 and LTE-M2. This growth is supported by 34 IoT Labs and an expanding community of over 800 organisations in the GSMA’s Mobile IoT Innovators Community. According to GSMA Intelligence forecasts, by 2025 there will be 3.1 billion cellular IoT connections, including 1.8 billion licensed LPWA connections. “2018 is the year that Mobile IoT networks will scale. We have seen huge growth in the availability of commercial networks in licensed spectrum and anticipate seeing many more launches this year. This is underpinned by an expanding community of organisations developing innovative new solutions and a number of IoT Labs helping companies to test out new products and services,” said Alex Sinclair, Chief Technology Officer, GSMA. “Mobile IoT ne

Clientron to Present Its POS Innovation at EuroCIS 201821.2.2018 09:00Pressemelding

Clientron Corp., a global leading provider of POS, thin client, and embedded systems, will display its latest POS solutions for the retail market at the world’s leading retail show, EuroCIS 2018, from February 27 to March 1, 2018 in Dusseldorf, Germany. At its Booth (Hall 10, Booth E73), Clientron will introduce its innovative POS terminals and various built-in POS peripherals available on the market today in order to meet the demands of omnicommerce experience. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005007/en/ Clientron to present its POS innovation at EuroCIS 2018 At the event, Clientron's displays will include: the innovative PST650 all-in-one POS terminal with a built-in high speed thermal printer and a small, lightweight form factor for counter space savings; the most affordable POS terminal, PT2000, in a fanless design with long life span support to both entry and mainstream POS market segments; and the ne

Fake Medicines Continue to Threaten Consumers – EU Member States have an Obligation to Act21.2.2018 08:12Pressemelding

According to The Alliance for Safe Online Pharmacy in the EU (ASOP EU), the illegal manufacturing and distribution of fake medicines is an enormous and growing public health risk with an untold cost to lives. "Vast profits are made by organized criminal gangs who often use the proceeds to support other criminal activities. The Internet provides the ideal channel to buy illegally distributed fake medicines. Price, convenience and secrecy have driven consumer demand, creating the perfect environment for over 35,000 illegally operating websites." Under article 85d of the Falsified Medicines Directive, each EU Member State is obliged to raise awareness about the risks of buying medicines online. To better understand how countries are meeting these obligations to educate and protect consumers, the European Union’s Alliance for Safe Online Pharmacy (ASOP EU) and the European Alliance for Access to Safe Medicines (EAASM), has convened a series of discussions with many Member States. Based on

Triton Digital Integrates Platform 161 with a2x® to Provide Marketers and Buyers with Access to Premium Digital Audio Advertising Inventory21.2.2018 08:00Pressemelding

Triton Digital®, the global technology and services leader to the digital audio and podcast industry, announced today the integration of its audio advertising marketplace, a2x®, with Platform 161, a leading DSP for advertisers, agencies and publishers. The integration provides Platform 161’s advertisers with the ability to add online audio from top-tier broadcasters and streaming music services to their programmatic, omnichannel buys through both open auction and private marketplace (PMP) deals. “We are proud to partner with Triton Digital to provide our marketers with access to a wide range of digital audio inventory from music services, live streaming radio, podcasts, and more through the a2x programmatic audio marketplace,” said Marco Kloots, CEO at Platform 161. “The personal, highly-engaging nature of digital audio will undeniably enhance our marketers omnichannel buys, enabling them to both scale their buys and connect with their target audience in a native, immersive manner acro

Posiflex Showcases Stylish New Line of Touch Screen Terminals and Self-Service & Interactive Kiosks at EuroCIS 201821.2.2018 08:00Pressemelding

Posiflex Technology, Inc. unveils an entirely new line of dynamic touch screen terminals that embodies a new era for Posiflex and point-of-sale hardware – the RT Series. With an elegant housing and a strikingly thin profile, the RT Series brings a modern aesthetic to the counter and makes a retail business look even more attractive. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005002/en/ Make Your Business Look More Attractive with Posiflex RT Series (Photo: Business Wire) Available in 15” (4:3) screen or 15.6” (16:9) widescreen, the RT Series provides multiple CPU selection from Intel Celeron all the way to Core i5 CPU to fit each unique need. The patented fanless technology allows the unit to run silently and perform in harsh environments that involves dust and liquid spills. “POS terminal is no longer just a cold and hard business tool; it has evolved to be an extension of the brand offering a more dynamic in-store

Arix Bioscience and Ipsen Sign a Strategic Agreement to Develop and Commercialise Innovative Therapies21.2.2018 07:00Pressemelding

Regulatory News: Arix Bioscience plc (LSE:ARIX) (“Arix”), a global healthcare and life science company supporting medical innovation, and Ipsen (Euronext: IPN; ADR:IPSEY), a global specialty-driven biopharmaceutical company focused on innovation and specialty care, today announced a strategic agreement to develop and commercialise innovative therapies. Arix will provide Ipsen with access to its unique network of professional and scientific advisors, and the chance to invest in opportunities in Arix’s new and existing businesses. In return, Ipsen will contribute research, development and commercial expertise to the partnership. Arix and Ipsen will collaborate to identify opportunities and jointly create new companies focused primarily on the development and commercialisation of innovative therapies for patients. Joe Anderson, Chief Executive Officer of Arix Bioscience plc, commented: “This agreement brings together Ipsen’s deep expertise in drug development and commercialization with Ar